- Price
- $330.95
- Day
- -1.86%
- Mkt Cap
- $64.39B
- 52W Range
- $244.82 – $377.54
- Volume
- 1.02M
- Beta
- 0.57
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Read full article
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Read full article
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Read full article
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Read full article
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies. “Cell and gene therapies have the potential to transform care for patients with serious and compl.
Read full article
Connor Clark and Lunn Investment Management Ltd. acquired a new stake in shares of Cencora, Inc. (NYSE: COR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,973 shares of the company's stock, valued at approximately $841,000. Several other
Read full article
Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.
Read full article
Advisors Capital Management LLC purchased a new stake in shares of Cencora, Inc. (NYSE: COR) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,644 shares of the company's stock, valued at approximately $748,000. Several other hedge funds and
Read full article
These healthcare companies can actually benefit from inflation.
Read full article